Abstract
HIV infection results in severe immune dysfunction with ensuing sequelae that includes characteristic opportunistic infections. Pneumocystis pneumonia (PCP) is one of the most common of these infections and is routinely treated with sulphamethaxazole (SMX). Although this drug is known to cause hypersensitivity adverse drug reactions (ADRs) in 0.1% of the general population, the incidence of these ADRs increases tenfold in the HIV-positive population. The HIV-1 trans-activator of transcription (HIV-1 Tat) together with the drug metabolite sulphamethaxazole-hydroxylamine (SMX-HA) have both been reported to be factors in these hypersensitivity ADRs. In this study, we use an inducible, Tat-expressing vector system to show that the level of Tat expression contributes to the cellular sensitivity of Jurkat T cells to SMX-HA. We further demonstrated that apoptosis is the likely mechanism by which this occurs. Thus, our data provide insight into the significant increase of SMX-related ADRs during the transition between HIV-1 infection and AIDS.
Similar content being viewed by others
References
M.C. Huigen, W. Kamp, H.S. Nottet, Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. Eur. J. Clin. Invest. 34(1), 57–66 (2004). doi:https://doi.org/10.1111/j.1365-2362.2004.01282.x
D.C. Douek, L.J. Picker, R.A. Koup, T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 21, 265–304 (2003). doi:https://doi.org/10.1146/annurev.immunol.21.120601.141053
A. Pugliese et al., A review of HIV-1 Tat protein biological effects. Cell Biochem. Funct. 23(4), 223–227 (2005). doi:https://doi.org/10.1002/cbf.1147
C. Brigati et al., HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol. Lett. 220(1), 57–65 (2003). doi:https://doi.org/10.1016/S0378-1097(03)00067-3
M.H. Malim et al., Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335(6186), 181–183 (1988). doi:https://doi.org/10.1038/335181a0
M. Li-Weber et al., T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB. Eur. J. Immunol. 30(2), 661–670 (2000). doi:https://doi.org/10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.0.CO;2-L
C. de la Fuente et al., Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals. BMC Biochem. 3, 14 (2002). doi:https://doi.org/10.1186/1471-2091-3-14
C. Ambrosino et al., HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J. Biol. Chem. 272(23), 14883–14892 (1997). doi:https://doi.org/10.1074/jbc.272.23.14883
K.J. Sastry et al., HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. J. Biol. Chem. 265(33), 20091–20093 (1990)
C.J. Li et al., Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92(12), 5461–5464 (1995). doi:https://doi.org/10.1073/pnas.92.12.5461
S.C. Flores et al., Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells. Proc. Natl. Acad. Sci. USA 90(16), 7632–7636 (1993). doi:https://doi.org/10.1073/pnas.90.16.7632
J. Choi et al., Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J. Biol. Chem. 275(5), 3693–3698 (2000). doi:https://doi.org/10.1074/jbc.275.5.3693
R. Buhl et al., Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 2(8675), 1294–1298 (1989). doi:https://doi.org/10.1016/S0140-6736(89)91909-0
F.J. Staal et al., Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals. AIDS Res. Hum. Retroviruses 8(2), 305–311 (1992)
S.L. Walmsley et al., Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS 11(14), 1689–1697 (1997). doi:https://doi.org/10.1097/00002030-199714000-00005
S.R. Bartz, M. Emerman, Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J. Virol. 73(3), 1956–1963 (1999)
M.O. Westendorp et al., Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375(6531), 497–500 (1995). doi:https://doi.org/10.1038/375497a0
A. Morris et al., Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10(10), 1713–1720 (2004)
P.A. Masters et al., Trimethoprim-sulfamethoxazole revisited. Arch. Intern. Med. 163(4), 402–410 (2003). doi:https://doi.org/10.1001/archinte.163.4.402
J.C. Roujeau, R.S. Stern, Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331(19), 1272–1285 (1994). doi:https://doi.org/10.1056/NEJM199411103311906
A. Carr et al., Patterns of multiple-drug hypersensitivities in HIV-infected patients. AIDS 7(11), 1532–1533 (1993)
C.M. Davis, W.T. Shearer, Diagnosis and management of HIV drug hypersensitivity. J. Allergy Clin. Immunol. 121(4), 826–832.e5 (2008)
D. Lin, M.J. Tucker, M.J. Rieder, Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann. Pharmacother. 40(9), 1594–1601 (2006). doi:https://doi.org/10.1345/aph.1G525
M.J. Rieder et al., Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J. Pharmacol. Exp. Ther. 244(2), 724–728 (1988)
D.A. Hess et al., Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole. FASEB J. 13(13), 1688–1698 (1999)
A. Carr et al., In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin. Exp. Immunol. 94(1), 21–25 (1993)
M.J. Rieder et al., Toxicity of sulfonamide-reactive metabolites in HIV-infected, HTLV-infected, and noninfected cells. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8(2), 134–140 (1995). doi:https://doi.org/10.1097/00042560-199502000-00004
J. Arp et al., Hypersensitivity of HIV-1-infected cells to reactive sulfonamide metabolites correlated to expression of the HIV-1 viral protein tat. J. Pharmacol. Exp. Ther. 314(3), 1218–1225 (2005). doi:https://doi.org/10.1124/jpet.105.085050
D. Calista et al., Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. Am. J. Clin. Dermatol. 3(1), 59–62 (2002). doi:https://doi.org/10.2165/00128071-200203010-00006
A.D. Frankel, C.O. Pabo, Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55(6), 1189–1193 (1988). doi:https://doi.org/10.1016/0092-8674(88)90263-2
C.A. Strathdee, M.R. McLeod, J.R. Hall, Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. Gene 229(1–2), 21–29 (1999). doi:https://doi.org/10.1016/S0378-1119(99)00045-1
M.L. Wong, J.F. Medrano, Real-time PCR for mRNA quantitation. Biotechniques 39(1), 75–85 (2005). doi:https://doi.org/10.2144/05391RV01
T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1–2), 55–63 (1983). doi:https://doi.org/10.1016/0022-1759(83)90303-4
D.R. Green, Apoptotic pathways: ten minutes to dead. Cell 121(5), 671–674 (2005). doi:https://doi.org/10.1016/j.cell.2005.05.019
R.N. Blum et al., Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J. Acquir. Immune Defic. Syndr. 5(4), 341–347 (1992)
J.R. Sullivan, N.H. Shear, The drug hypersensitivity syndrome: what is the pathogenesis? Arch. Dermatol. 137(3), 357–364 (2001)
M.J. Rieder, G.A. Dekaban, Deja vu all over again: adverse reactions to nonnucleoside reverse transcriptase inhibitors. Ann. Pharmacother. 34(7–8), 940–942 (2000). doi:https://doi.org/10.1345/aph.10064
C. Paul et al., Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br. J. Dermatol. 134(4), 710–714 (1996). doi:https://doi.org/10.1111/j.1365-2133.1996.tb06976.x
P. Paquet, G.E. Pierard, Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int. J. Mol. Med. 10(2), 145–147 (2002)
R. Abe et al., Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am. J. Pathol. 162(5), 1515–1520 (2003)
A. Lewen et al., Oxidative stress-dependent release of mitochondrial cytochrome c after traumatic brain injury. J. Cereb. Blood Flow Metab. 21(8), 914–920 (2001). doi:https://doi.org/10.1097/00004647-200108000-00003
P.G. Sullivan et al., Cytochrome c release and caspase activation after traumatic brain injury. Brain Res. 949(1–2), 88–96 (2002). doi:https://doi.org/10.1016/S0006-8993(02)02968-2
C.J. Li et al., Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268(5209), 429–431 (1995). doi:https://doi.org/10.1126/science.7716549
I.W. Park et al., HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J. Immunol. 167(5), 2766–2771 (2001)
C.C. Liu et al., Apoptosis, complement and systemic lupus erythematosus: a mechanistic view. Curr. Dir. Autoimmun. 7, 49–86 (2004). doi:https://doi.org/10.1159/000075687
A.C. Rego, C.R. Oliveira, Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res. 28(10), 1563–1574 (2003). doi:https://doi.org/10.1023/A:1025682611389
M. Jaattela, Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 23(16), 2746–2756 (2004). doi:https://doi.org/10.1038/sj.onc.1207513
S.M. Raidel et al., Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am. J. Physiol. Heart Circ. Physiol. 282(5), H1672–H1678 (2002)
M.O. Westendorp et al., HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J. 14(3), 546–554 (1995)
K. Muthumani et al., Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem. Biophys. Res. Commun. 304(3), 583–592 (2003). doi:https://doi.org/10.1016/S0006-291X(03)00631-4
V.S. Yedavalli et al., Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J. Virol. 79(21), 13735–13746 (2005). doi:https://doi.org/10.1128/JVI.79.21.13735-13746.2005
Y. Yang, Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J. Virol. 77(12), 6700–6708 (2003). doi:https://doi.org/10.1128/JVI.77.12.6700-6708.2003
Acknowledgments
This work was supported by grants from the Canadian Institutes for Health Research (CIHR) and the CIHR-GSK Chair in Paediatric Clinical Pharmacology (to M.J.R.) and a CHIR Canada Graduate Scholarships Doctoral Award (to K.A.).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Kemi Adeyanju and Adriana Krizova contributed equally to this article.
Rights and permissions
About this article
Cite this article
Adeyanju, K., Krizova, A., Gilbert, P.A. et al. HIV Tat potentiates cell toxicity in a T cell model for sulphamethoxazole-induced adverse drug reactions. Virus Genes 38, 372–382 (2009). https://doi.org/10.1007/s11262-009-0344-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11262-009-0344-3